期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲磺酸伊马替尼临床研究概况 被引量：12

The Advances in Clinical Study of Imatinib Mesilate
下载PDF
导出
摘要 甲磺酸伊马替尼是一种蛋白质酪氨酸激酶抑制剂,用于治疗Ph染色体阳性慢性粒细胞白血病和恶性胃肠道间质肿瘤。本文从耐药机制、不良反应、生活质量考察、药物经济学成本-效用分析等方面综述了其最新临床研究进展。 Imatinib mesilate is a protein-tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and malignant gastrointestinal stromal tumors. In this article we reviewed the advances in clinical study of imatinib including its mechanism of resistance,adverse events,life quality study and cost-effective analysis ,etc.
作者 郑斌 危晴岚 刘茂柏
机构地区 福建医科大学附属协和医院
出处 《海峡药学》 2006年第6期78-80,共3页 Strait Pharmaceutical Journal
关键词 甲磺酸伊马替尼 慢性粗细胞白血病 耐药机制 不良反应 Imatinib mesilate Chronic myelogenous leukemia Mechanism of resistance Adverse events
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献18

  • 1Cohen MH,Williams G,Johnson JR,et al.Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia[J].Clin Cancer Res.2002 May;8(5):935～42.
  • 2Dagher R,Cohen M,Williams G,et al.Approval summary:imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors[J].Clin Cancer Res.2002 Oct;8(10):3034～8.
  • 3俞文娟.STI571的耐药机制及其克服对策[J].国外医学（输血及血液学分册）,2003,26(3):260-264. 被引量：3
  • 4Donato NJ,Wu JY,Stapley J,et al.Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia[J].Cancer Res,2004,64(2):672～677.
  • 5Gambacorti-Passerini C,Barni R,Ie Coutre P,et al.Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.J Natl Cancer Inst,2000,92(20:1641-50.
  • 6Gambacorti-Passerini C,Corneo G,D'Incalci M.Roots of clinical resistance to STI-571 cancer therapy.Science,2001,293(5538):2163.
  • 7Rumpold H,Wolf AM,Gruenewald K,et al.RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durable restores imatinib sensitivity in imatinib-resistant CML cell lines[J].Exp Hematol,2005,33(7):767～775.
  • 8Luzzatto L,Frassoni F,Melo JV.Imatinib:can one outwit chronic myeloid leukemia?[J].Haematologica,2002,(9):898-901.
  • 9Weisberg E,Manley P,Mestan J,et al.AMN107 (nilotinib):a novel and selective inhibitor of BCR-ABL[J].Br J Cancer,2006,May 23.
  • 10Mohi MG,Boulton C,Gu TI,et al.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs[J].Proc Natl Acad Sci USA,2004,101(9):3130～3135.

二级参考文献24

  • 1Pastemak G, Hochhaus A, Schultheis B, et al. J Cancer Res Clin Oncol,1998.124:643.
  • 2Lugo TG, Pendergast AM, Muller AJ, et al. Science, 1990,247: 824.
  • 3Le Coutre P, Mologni L, Cleris L, et al. J Natl Cancer Inst, 1999,91 :163.
  • 4Gorre EM, Mohammed M, Elwood K, et al. Science,2001,293: 876.
  • 5Roche - Lestienne C, Soenen - Comu V, Gradel - Duflos N, et al.Blood, 2002,100 : 1014.
  • 6Bathe C,Cony- Makhoul P, Melo JV, et al. Science,2001,293:2163.
  • 7Hochhaus A,Kreil S,Corbin A, et al. Science,2001,293:2163.
  • 8Budoff NV, Folker F, Pesehel C, et al. Lancet, 2002,359 : 487.
  • 9Le Coutre P, Tassi E, Varella - Garcia M, et al. Blood, 2000,95 : 1758.
  • 10Mahon FX, Deininger MW,Schultheis B, et al. Blood,2000,96 : 1070.

共引文献2

同被引文献114

引证文献12

二级引证文献29

海峡药学
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部